药学学报, 2018, 53(9): 1551-1556
引用本文:
高明月, 霍英楠, 申欣, 毛世瑞. 改良的在体循环法用于胰岛素的鼻腔吸收研究[J]. 药学学报, 2018, 53(9): 1551-1556.
GAO Ming-yue, HUO Ying-nan, SHEN Xin, MAO Shi-rui. Modification of in situ perfusion in study of nasal absorption of insulin[J]. Acta Pharmaceutica Sinica, 2018, 53(9): 1551-1556.

改良的在体循环法用于胰岛素的鼻腔吸收研究
高明月, 霍英楠, 申欣, 毛世瑞
沈阳药科大学药学院, 辽宁 沈阳 110016
摘要:
本文建立了一种适用于胰岛素鼻腔吸收研究的在体实验方法。首先,考察在体鼻循环实验方法对胰岛素的适用性,结果发现,胰岛素存在一定的管路吸附,传统方法不适用于胰岛素的研究;而在循环液中加入0.001% Labrasol可以有效解决胰岛素的管路吸附问题,该改良方法可用于胰岛素鼻腔吸收研究。采用该方法考察pH和药物浓度对胰岛素鼻腔吸收的影响,结果表明,相比于pH 4.5和pH 7.4,药物在pH 6.0的条件下吸收速度最低。同时,胰岛素的鼻腔吸收机制可能是基于浓度梯度的被动扩散。
关键词:    胰岛素      鼻腔在体循环      鼻腔吸收      管路吸附      表面活性剂     
Modification of in situ perfusion in study of nasal absorption of insulin
GAO Ming-yue, HUO Ying-nan, SHEN Xin, MAO Shi-rui
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract:
The objective of this study is to develop an in vitro screening method for nasal absorption of insulin. First, the adaptability of in situ rat nasal perfusion test for the study of insulin was investigated. It was found that insulin was liable to be absorbed on the silicone tube and the traditional method is not suitable. However, addition of 0.001% Labrasol into the perfusate can effectively solve this problem. A modified method suitable for in situ rat nasal perfusion of insulin was established with the addition of 0.001% Labrasol into the perfusate. Using the modified method, effect of pH and drug concentration on the absorption of insulin in the nasal cavity was further investigated. The results suggest that compared with pH 4.5 and pH 7.4, the drug absorption rate was the lowest at pH 6.0. The intranasal absorption mechanism of insulin may be passive diffusion.
Key words:    insulin    in situ nasal perfusion    nasal absorption    tube absorption    surfactant   
收稿日期: 2018-05-22
DOI: 10.16438/j.0513-4870.2018-0478
基金项目: 辽宁特聘教授基金项目资助(2015).
通讯作者: 毛世瑞,Tel/Fax:86-24-43520523,E-mail:maoshirui@syphu.edu.cn
Email: maoshirui@syphu.edu.cn
相关功能
PDF(284KB) Free
打印本文
0
作者相关文章
高明月  在本刊中的所有文章
霍英楠  在本刊中的所有文章
申欣  在本刊中的所有文章
毛世瑞  在本刊中的所有文章

参考文献:
[1] Yu M, Wu J, Shi J, et al. Nanotechnology for protein delivery:overview and perspectives[J]. J Control Release, 2016, 240:24-37.
[2] Yamamoto A, Hayakawa E, Lee VH. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit:implications in peptide delivery from nonoral routes[J]. Life Sci, 1990, 47:2465-2474.
[3] Kamei N, Tanaka M, Choi H, et al. Effect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouse[J]. Mol Pharmaceut, 2017, 14:916-927.
[4] Salameh TS, Bullock KM, Hujoel IA, et al. Central nervous system delivery of intranasal insulin:mechanisms of uptake and effects on cognition[J]. J Alzheimers Dis, 2015, 47:715-728.
[5] Freiherr J, Hallschmid M, Frey WH, et al. Intranasal insulin as a treatment for Alzheimer's disease:a review of basic research and clinical evidence[J]. CNS Drugs, 2013, 27:505-514.
[6] Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage alzheimer's disease dementia[J]. J Alzheimers Dis, 2015, 44:897-906.
[7] Davis SS, Illum L. Absorption enhancers for nasal drug delivery[J]. Clin Pharmacokinet, 2003, 42:1107-1128.
[8] Shinichiro H, Takatsuka Y, Tai M, et al. Absorption of drugs from the nasal mucosa of rat[J]. Int J Pharm, 1981, 7:317-325.
[9] Ran M. Prevention of the absorption of insulin in the containers.[J]. World Clin Drugs (世界临床药物), 1986, 1:64-65.
[10] Na L, Wang J, Wang L, et al. A novel permeation enhancer:n-succinyl chitosan on the intranasal absorption of isosorbide dinitrate in rats[J]. Eur J Pharm Sci, 2013, 48:301-306.
[11] Song X, Du S, Lu Y, et al. Study on rat nasal absorption in situ of borneol based on single pass perfusion method[J]. China J Chin Mater Med (中国中药杂志), 2011, 36:2489-2492.
[12] Wang H, Wei G, Gao M, et al. Intranasal absorption of rivastigmine hydrogen tartrate and brain targeting evaluation[J]. Acta Pharm Sin (药学学报), 2016, 51:1616-1621.
[13] Lee VHL, Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption[J]. Adv Drug Deliv Rev, 1989, 4:171-207.
[14] Thurow H, Geisen K. Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces[J]. Diabetologia, 1984, 27:212-218.
[15] Wang J, Sakai S, Deguchi Y, et al. Aminated gelatin as a nasal absorption enhancer for peptide drugs:evaluation of absorption enhancing effect and nasal mucosa perturbation in rats[J]. J Pharm Pharmacol, 2002, 54:181-188.